UTILIZING PREDICTIVE BIOMARKERS TO IMPROVE TREATMENT OUTCOMES IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): RESULTS WITH CETUXIMAB PLUS FOLFIRI IN THE CRYSTAL TRIAL

被引：0
|
作者：
Rougier, P. [1 ]
Janciauskiene, R. [2 ]
Paramonov, V [3 ]
Shparyk, Y. [4 ]
Gustavsson, B. [5 ]
Wagnerova, M. [6 ]
Gorbunova, V [7 ]
Utracka-Hutka, B. [8 ]
Celik, I [9 ]
Van Cutsem, E. [10 ]
机构：
[1] Hop Ambroise Pare, Boulogne, France
[2] Kauno Med Univ Klin, Kaunas, Lithuania
[3] Cherkassy Oblasnoy Onkodispanser, Charkassy, Ukraine
[4] Lviv Oncol Med & Diagnost Ctr, Lvov, Ukraine
[5] Sahlgrens Univ Hosp, Gothenburg, Sweden
[6] Vychodoslovensky Onkol Ustav, Kosice, Slovakia
[7] RAMN, NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[8] MSC Mem Canc Ctr, Gliwice, Poland
[9] Merck KGaA, Darmstadt, Germany
[10] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [11] Safety and effectiveness of aflibercept plus FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses
    Chau, I.
    Fakih, M. G.
    Garcia-Alfonso, P.
    Linke, Z.
    Ruiz-Casado, A.
    Polo Marques, E.
    Picard, P.
    Celanovic, M.
    Cartwright, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 227 - 227
  • [12] Somatic Alterations and Tumor Mutational Burden (TMB) in Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFiRI Plus Bevacizumab or Cetuximab (Fire-3 Trial)
    Stahler, Arndt
    Stintzing, Sebastian
    von Einem, Jobst C.
    Westphalen, C. Benedikt
    Kraemer, Nicole
    Michl, Marlies
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Heintges, Tobias
    Kahl, Christoph
    Kullmann, Frank
    Scheithauer, Werner
    Moehler, Markus
    Vehling-Kaiser, Ursula
    Kirchner, Thomas
    Jung, Andreas
    Heinemann, Volker
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 48 - 48
  • [13] Predictive biomarkers of response to cetuximab in Chinese patients with metastatic colorectal cancer
    Ma, Brigette
    Loong, Herbert
    Liem, Giok Siong
    Mo, Frankie
    Tong, Joanna
    Wong, S. C. Cesar
    Chan, Anthony T. C.
    To, Ka Fai
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [14] KRAS STATUS AND EFFICACY IN THE CRYSTAL STUDY: 1ST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING FOLFIRI WITH OR WITHOUT CETUXIMAB
    Van Cutsem, Eric
    Lang, Istvan
    D'Haens, Geerts
    Moiseyenko, Vladimir
    Zaluski, Jerzy
    Folprecht, Gunnar
    Tejpar, Sabine
    Nippgen, Johannes
    Stroh, Christopher
    Rougier, Philippe
    ANNALS OF ONCOLOGY, 2008, 19 : 4 - 4
  • [15] Molecular profiling of the CAPRI GOIM trial in KRAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pts): Cetuximab plus FOLFIRI followed by FOLFOX4 ± cetuximab
    Ciardiello, F.
    Normanno, N.
    Maiello, E.
    Martinelli, E.
    Troiani, T.
    Rachiglio, A. M.
    Giuliani, F.
    Pisconti, S.
    Barone, C.
    Colucci, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S14 - S14
  • [16] Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
    Elena Élez
    María Auxiliadora Gómez-España
    Cristina Grávalos
    Pilar García-Alfonso
    María José Ortiz-Morales
    Ferrán Losa
    Inmaculada Alés Díaz
    Begoña Graña
    Marta Toledano-Fonseca
    Manuel Valladares-Ayerbes
    Eduardo Polo
    Mercedes Salgado
    Eva Martínez de Castro
    María José Safont
    Antonieta Salud
    Ana Ruiz-Casado
    Josep Tabernero
    María del Carmen Riesco
    Antonio Rodriguez-Ariza
    Enrique Aranda
    British Journal of Cancer, 2022, 126 : 874 - 880
  • [17] Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).
    Tebbutt, N. C.
    Kotasek, D.
    Burris, H. A., III
    Schwartzberg, L. S.
    Hurwitz, H.
    Stephenson, J.
    Adewoye, H.
    Sun, Y.
    Ye, Y.
    Goldstein, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [18] Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).
    Nixon, Andrew B.
    Sibley, Alexander
    Hatch, Ace Joseph
    Liu, Yingmiao
    Jiang, Chen
    Mulkey, Flora
    Starr, Mark D.
    Brady, John C.
    Niedzwiecki, Donna
    Innocenti, Federico
    Venook, Alan P.
    Hochster, Howard S.
    Lenz, Heinz-Josef
    O'Neil, Bert H.
    Owzar, Kouros
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [19] Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.
    Ciardiello, Fortunato
    Lenz, Heinz-Josef
    Kohne, Claus-Henning
    Heinemann, Volker
    Tejpar, Sabine
    Melezinek, Ivan
    Beier, Frank
    Stroh, Christopher
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [20] CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC).
    Ziras, N.
    Polyzos, A.
    Xenidis, N.
    Kalykaki, A.
    Androulakis, N. E.
    Papakotoulas, P.
    Kentepozidis, N. K.
    Makrantonakis, P.
    Xynogalos, S.
    Sougklakos, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345